- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
- Vistagen to Present at Stifel 2024 Virtual CNS Days
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference
More ▼
Key statistics
On Wednesday, Vistagen Therapeutics Inc (VTGN:NAQ) closed at 4.26, 162.96% above the 52 week low of 1.62 set on Jun 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.38 |
---|---|
High | 4.42 |
Low | 4.26 |
Bid | 4.19 |
Offer | 4.75 |
Previous close | 4.26 |
Average volume | 103.58k |
---|---|
Shares outstanding | 27.03m |
Free float | 26.97m |
P/E (TTM) | -- |
Market cap | 115.13m USD |
EPS (TTM) | -3.56 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼